Copyright
©The Author(s) 2017.
World J Hepatol. Feb 18, 2017; 9(5): 270-277
Published online Feb 18, 2017. doi: 10.4254/wjh.v9.i5.270
Published online Feb 18, 2017. doi: 10.4254/wjh.v9.i5.270
Table 1 Baseline characteristics of 102 patients
| Parameters | Description |
| Age (mean ± SD) | 58.35 ± 6.62 |
| Gender (male:female) | 63:39 |
| Child-Pugh class (A:B:C) | 43:32:27 |
| Etiology (Alcohol:Viral:NASH or Cryptogenic:AIH) | 31:37:29:5 |
| Oesophagea l Varices (small:large) | 34:68 |
| Ascites (No:Grade I:Grade II: Grade III) | 63:6:25:8 |
| Total bilirubin (mg/dL) | 1.96 ± 0.81 |
| Serum albumin (mg/dL) | 3.20 ± 0.49 |
| Prothrombin time | 14.13 ± 1.91 |
| International normalized ratio | 1.29 ± 0.16 |
- Citation: Wani ZA, Mohapatra S, Khan AA, Mohapatra A, Yatoo GN. Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension. World J Hepatol 2017; 9(5): 270-277
- URL: https://www.wjgnet.com/1948-5182/full/v9/i5/270.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i5.270